The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Blood screening for MGUS: preventing progression with PROMISE
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, gives us an update on the exciting PROMISE study, which performs a simple blood screening procedure on those at high-risk of developing myeloma, including African Americans and those with a family history of the disease. This would enable the early detection and treatment of MGUS and/or smoldering myeloma, with the aim of preventing disease progression. With the study well underway, she covers what has been found so far and how the results may effect practice. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
